NK042 cell therapy for malignant ascites in gynecologic cancers
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called NK042 for people with advanced gynecologic cancers like ovarian or endometrial cancer that cause fluid buildup in the belly (malignant ascites). The goal is to see if it is safe and can help reduce the fluid and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a gynecologic cancer such as ovarian or endometrial cancer that has spread and caused fluid in your belly (at least 1 liter).
- You are well enough to have a life expectancy of at least 3 months and can manage daily activities (ECOG score 0-2).
- Your blood counts, kidney, and liver function are within acceptable ranges.
- You are willing to use reliable birth control during the trial and for at least 1 year after the last dose if you are able to have children.
- You have not had recent treatments for the belly fluid (like paracentesis) or other experimental therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy called NK521 for people with advanced solid tumors like liver or ovarian cancer that have not responded to standard treatment. The therapy may be given as an infusion or into the belly (for those with fluid buildup containing cancer cells).
This trial tests a new therapy that uses your own natural killer (NK) cells, modified to better fight cancer and injected directly into your abdomen. It's for people with advanced ovarian cancer who cannot have surgery or whose tumor cannot be fully removed.
This trial tests an experimental natural killer (NK) cell therapy for advanced solid tumors that also cause fluid buildup in the abdomen (malignant ascites). It may help shrink tumors and reduce fluid, but it's very early stage (phase 1/2), so safety and effectiveness are still being studied.
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
Hear when a new Gynecologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.